The efficacy of immune checkpoint inhibitors is limited in elderly NSCLC: a retrospective efficacy study and meta-analysis
Jiaxin Yin(Wuhan University), Bicheng Zhang(University of Electronic Science and Technology of China), Jun Wang(Shenzhen Bao'an District People's Hospital), Zhimin Zhang(Wuhan University), Jiazhuo Tang(Wuhan University), Yang Fu(First Affiliated Hospital of Zhengzhou University), Yuxiao Song(Wuhan University), Qibin Song(Wuhan University)
Cited by 14
Related Papers
Clinical characteristics of 82 cases of death from COVID-19
|PLoS ONE|2020|594
Immune Phenotyping Based on the Neutrophil-to-Lymphocyte Ratio and IgG Level Predicts Disease Severity and Outcome for Patients With COVID-19
|Frontiers in Molecular Biosciences|2020|497
Prognostic Value of C-Reactive Protein in Patients With Coronavirus 2019
|Clinical Infectious Diseases|2020|458
Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment
|Frontiers in Immunology|2020|256
Clinical characteristics of 82 death cases with COVID-19
|medRxiv|2020|249